Celsion Co. (NASDAQ:CLSN) shares saw strong trading volume on Thursday . 2,914,104 shares traded hands during mid-day trading, an increase of 146% from the previous session’s volume of 1,185,848 shares.The stock last traded at $2.78 and had previously closed at $2.78.
A number of equities research analysts have recently issued reports on the company. ValuEngine lowered Celsion from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 15th. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, October 4th. Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Oppenheimer began coverage on Celsion in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.90.
The stock has a market capitalization of $44.65, a price-to-earnings ratio of -0.47 and a beta of 1.22.
COPYRIGHT VIOLATION WARNING: “Celsion (CLSN) Sees Large Volume Increase” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/01/04/celsion-clsn-sees-large-volume-increase.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.